Burling Wealth Partners LLC Has $2.61 Million Stock Position in AstraZeneca PLC $AZN

Burling Wealth Partners LLC lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 21.0% in the second quarter, HoldingsChannel reports. The firm owned 37,273 shares of the company’s stock after selling 9,889 shares during the period. Burling Wealth Partners LLC’s holdings in AstraZeneca were worth $2,605,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after acquiring an additional 2,789 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of AstraZeneca by 115.4% in the first quarter. Nisa Investment Advisors LLC now owns 1,400 shares of the company’s stock valued at $103,000 after purchasing an additional 750 shares during the last quarter. Xponance Inc. raised its position in shares of AstraZeneca by 6.9% in the first quarter. Xponance Inc. now owns 3,465 shares of the company’s stock valued at $255,000 after purchasing an additional 224 shares during the period. New York State Common Retirement Fund lifted its stake in shares of AstraZeneca by 1.7% during the 1st quarter. New York State Common Retirement Fund now owns 135,357 shares of the company’s stock worth $9,949,000 after buying an additional 2,314 shares during the last quarter. Finally, Sigma Planning Corp boosted its holdings in shares of AstraZeneca by 10.1% during the 1st quarter. Sigma Planning Corp now owns 4,529 shares of the company’s stock worth $333,000 after buying an additional 417 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $88.61 on Friday. The business has a fifty day moving average price of $81.98 and a two-hundred day moving average price of $76.04. The stock has a market capitalization of $274.82 billion, a PE ratio of 33.31, a P/E/G ratio of 1.52 and a beta of 0.34. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $89.43.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.AstraZeneca’s revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business earned $2.08 earnings per share. As a group, equities analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on AZN. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.